NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date (Ascending) | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
67457-0769-02 | 67457-0769 | ONDANSETRON HYDROCHLORIDE | ONDANSETRON HYDROCHLORIDE | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 31, 2017 | In Use | |
68001-0534-36 | 68001-0534 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | July 31, 2022 | In Use | |
68001-0541-36 | 68001-0541 | Bortezomib | Bortezomib | 3.5 mg/3.5mL | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | July 31, 2022 | In Use | |
68788-8223-01 | 68788-8223 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 12, 2022 | In Use | |
68788-8223-03 | 68788-8223 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 12, 2022 | In Use | |
68788-8223-05 | 68788-8223 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 12, 2022 | In Use | |
68788-8223-06 | 68788-8223 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 12, 2022 | In Use | |
68788-8267-02 | 68788-8267 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 23, 2022 | In Use | |
68788-8267-03 | 68788-8267 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 23, 2022 | In Use | |
68001-0559-69 | 68001-0559 | Methylprednisolone | Methylprednisolone | 16.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 29, 2022 | In Use | |
68001-0543-41 | 68001-0543 | Pemetrexed disodium | Pemetrexed | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 1, 2022 | In Use | |
68001-0544-41 | 68001-0544 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 1, 2022 | In Use | |
68001-0550-41 | 68001-0550 | Pemetrexed disodium | Pemetrexed | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 7, 2022 | In Use | |
68001-0551-41 | 68001-0551 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 7, 2022 | In Use | |
68001-0552-41 | 68001-0552 | Pemetrexed disodium | Pemetrexed | 850.0 mg/34mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 7, 2022 | In Use | |
68001-0553-41 | 68001-0553 | Pemetrexed disodium | Pemetrexed | 1000.0 mg/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 7, 2022 | In Use | |
68001-0557-00 | 68001-0557 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 29, 2022 | In Use | |
68001-0558-55 | 68001-0558 | Methylprednisolone | Methylprednisolone | 8.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 29, 2022 | In Use | |
69339-0171-03 | 69339-0171 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 24, 2022 | In Use | |
69339-0171-05 | 69339-0171 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 24, 2022 | In Use | |
69339-0172-03 | 69339-0172 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 24, 2022 | In Use | |
69339-0172-05 | 69339-0172 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 24, 2022 | In Use | |
70518-3401-00 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 5, 2022 | In Use | |
70518-3401-01 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 5, 2022 | In Use | |
70518-3401-02 | 70518-3401 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 9, 2022 | In Use | |
68001-0560-55 | 68001-0560 | Methylprednisolone | Methylprednisolone | 32.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 29, 2022 | In Use | |
68071-2771-06 | 68071-2771 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 15, 2022 | In Use | |
68071-2771-01 | 68071-2771 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 15, 2022 | In Use | |
68788-8276-02 | 68788-8276 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 14, 2022 | In Use | |
69097-0381-73 | 69097-0381 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sept. 6, 2022 | In Use | |
69097-0382-73 | 69097-0382 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sept. 6, 2022 | In Use | |
69097-0383-81 | 69097-0383 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sept. 6, 2022 | In Use | |
69097-0385-81 | 69097-0385 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sept. 6, 2022 | In Use | |
69097-0909-50 | 69097-0909 | Leuprolide acetate | LEUPROLIDE ACETATE DEPOT | Hormonal Therapy | GnRH Agonist | July 15, 2022 | In Use | ||||
70121-1233-01 | 70121-1233 | Pemetrexed | Pemetrexed disodium | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Aug. 10, 2022 | In Use | |
70511-0161-05 | 70511-0161 | Bortezomib | Bortezomib | 1.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous | Aug. 11, 2022 | In Use | |
70511-0162-02 | 70511-0162 | Bortezomib | Bortezomib | 2.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous | Aug. 11, 2022 | In Use | |
70518-2138-00 | 70518-2138 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | June 12, 2019 | In Use | |
70518-2138-01 | 70518-2138 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 10, 2021 | In Use | |
70518-2138-02 | 70518-2138 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 3, 2022 | In Use | |
70518-2138-03 | 70518-2138 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 9, 2022 | In Use | |
70518-2982-00 | 70518-2982 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 7, 2021 | In Use | |
70518-3263-00 | 70518-3263 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Nov. 2, 2021 | In Use | |
70518-3263-01 | 70518-3263 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Feb. 15, 2022 | In Use | |
70518-3263-03 | 70518-3263 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Sept. 11, 2022 | In Use | |
70518-3263-04 | 70518-3263 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct. 19, 2022 | In Use | |
70518-3458-01 | 70518-3458 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 4.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Intravenous, Soft Tissue | July 22, 2022 | In Use | |
70518-3512-00 | 70518-3512 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 7, 2022 | In Use | |
70518-3512-01 | 70518-3512 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 29, 2022 | In Use | |
70518-3537-00 | 70518-3537 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 27, 2022 | In Use |
Found 9,752 results in 12 milliseconds — Export these results